| [1] |
Wang YN, Zhou XJ, Chen P, et al. Interaction between GALNT12 and C1GALT1 associates with galactose-deficient IgA1 and IgA nephropathy [J]. J Am Soc Nephrol, 2021, 32(3): 545-552.
|
| [2] |
Dotz V, Visconti A, Lomax-Browne HJ, et al. O- and N-glycosylation of serum immunoglobulin A is associated with IgA nephropathy and glomerular function [J]. J Am Soc Nephrol, 2021, 32(10): 2455-2465.
|
| [3] |
Wheeler DC, Toto RD, Stefansson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy [J]. Kidney Int, 2021, 100(1): 215-224.
|
| [4] |
Xie D, Zhao H, Xu X, et al. Intensity of macrophage infiltration in glomeruli predicts response to immunosuppressive therapy in patients with IgA nephropathy [J]. J Am Soc Nephrol, 2021, 32(12): 3187-3196.
|
| [5] |
Canney M, Barbour SJ, Zheng Y, et al. Quantifying duration of proteinuria remission and association with clinical outcome in iga nephropathy [J]. J Am Soc Nephrol, 2021, 32(2): 436-447.
|
| [6] |
Sethi S, Madden B, Debiec H, et al. Protocadherin 7-associated membranous nephropathy [J]. J Am Soc Nephrol, 2021, 32(5): 1249-1261.
|
| [7] |
Al-Rabadi LF, Caza T, Trivin-Avillach C, et al. Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy [J]. J Am Soc Nephrol, 2021, 32(7): 1666-1681.
|
| [8] |
Caza TN, Hassen SI, Kuperman M, et al. Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis [J]. Kidney Int, 2021, 100(1): 171-181.
|
| [9] |
Fernandez-Juarez G, Rojas-Rivera J, Logt AV, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy [J]. Kidney Int, 2021, 99(4): 986-998.
|
| [10] |
Scolari F, Delbarba E, Santoro D, et al. Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial [J]. J Am Soc Nephrol, 2021, 32(4): 972-982.
|
| [11] |
Zonozi R, Laliberte K, Huizenga NR, et al. Combination of rituximab, low-dose cyclophosphamide, and prednisone for primary membranous nephropathy: a case series with extended follow up [J]. Am J Kidney Dis, 2021, 78(6): 793-803.
|
| [12] |
Delafosse M, Ponlot E, Esteve E, et al. Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy [J]. Kidney Int, 2021, 99(4): 1023-1024.
|
| [13] |
Haukka J, Sandholm N, Valo E, et al. Novel linkage peaks discovered for diabetic nephropathy in individuals with type 1 diabetes [J]. Diabetes, 2021, 70(4): 986-995.
|
| [14] |
Anderson AH, Xie D, Wang X, et al. Novel risk factors for progression of diabetic and nondiabetic CKD: findings from the chronic renal insufficiency cohort (CRIC) study [J]. Am J Kidney Dis, 2021, 77(1): 56-73.
|
| [15] |
Schrauben SJ, Shou H, Zhang X, et al. Association of multiple plasma biomarker concentrations with progression of prevalent diabetic kidney disease: findings from the chronic renal insufficiency cohort (CRIC) study [J]. J Am Soc Nephrol, 2021, 32(1): 115-126.
|
| [16] |
Wheeler DC, Stefánsson BV, Jongs N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial [J]. Lancet Diabetes Endocrinol, 2021, 9(1): 22-31.
|
| [17] |
Heerspink HJL, Jongs N, Chertow GM, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial [J]. Lancet Diabetes Endocrinol, 2021, 9(11): 743-754.
|
| [18] |
Jongs N, Greene T, Chertow GM, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial [J]. Lancet Diabetes Endocrinol, 2021, 9(11): 755-766.
|
| [19] |
Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease [J]. N Engl J Med, 2021, 384(2): 129-139.
|
| [20] |
Heerspink HJL, Kohan DE, de Zeeuw D. New insights from sonar indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction [J]. Kidney Int, 2021, 99(2): 346-349.
|
| [21] |
Ravindran A, Casal Moura M, Fervenza FC, et al. In patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes [J]. J Am Soc Nephrol, 2021, 32(3): 695-706.
|
| [22] |
Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial [J]. Lancet, 2021, 397(10289): 2070-2080.
|
| [23] |
Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis [J]. Arthritis Rheumatol, 2021, 73(1): 121-131.
|
| [24] |
Rovin BH, Furie R, Teng YKO, et al. A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis [J]. Kidney Int, 2021, 101(2): 403-413.
|
| [25] |
Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis [J]. Arthritis Rheumatol, 2021, 73(8): 1366-1383.
|
| [26] |
Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis [J]. N Engl J Med, 2021, 384(7): 599-609.
|
| [27] |
Gulati K, Edwards H, Prendecki M, et al. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis [J]. Kidney Int, 2021, 100(6): 1316-1324.
|
| [28] |
Nasr SH, Fidler ME, Said SM, et al. Immunofluorescence staining for immunoglobulin heavy chain/light chain on kidney biopsies is a valuable ancillary technique for the diagnosis of monoclonal gammopathy-associated kidney diseases [J]. Kidney Int, 2021, 100(1): 155-170.
|
| [29] |
Javaugue V, Pascal V, Bender S, et al. RNA-based immunoglobulin repertoire sequencing is a new tool for the management of monoclonal gammopathy of renal (kidney) significance [J]. Kidney Int, 2021, 101(2): 331-337.
|
| [30] |
Zand L, Rajkumar SV, Leung N, et al. Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits [J]. J Am Soc Nephrol, 2021, 32(5): 1163-1173.
|
| [31] |
Nasr SH, Kudose SS, Said SM, et al. Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants [J]. Kidney Int, 2021, 99(2): 410-420.
|
| [32] |
Mohammad KN, Chan EYY, Lau SY, et al. Relationship between acute kidney injury, seasonal influenza, and environmental factors: a 14-year retrospective analysis [J]. Environ Int, 2021, 153: 106521.
|
| [33] |
Ikizler TA, Parikh CR, Himmelfarb J, et al. A prospective cohort study of acute kidney injury and kidney outcomes, cardiovascular events, and death [J]. Kidney Int, 2021, 99(2): 456-465.
|
| [34] |
Hapca S, Siddiqui MK, Kwan RSY, et al. The relationship between AKI and CKD in patients with type 2 diabetes: an observational cohort study [J]. J Am Soc Nephrol, 2021, 32(1): 138-150.
|
| [35] |
Wilson FP, Martin M, Yamamoto Y, et al. Electronic health record alerts for acute kidney injury: multicenter, randomized clinical trial [J]. BMJ, 2021, 372: m4786.
|
| [36] |
Lodise TP, Drusano G. Vancomycin area under the curve-guided dosing and monitoring for adult and pediatric patients with suspected or documented serious methicillin-resistant staphylococcus aureus infections: putting the safety of our patients first [J]. Clin Infect Dis, 2021, 72(9): 1497-1501.
|
| [37] |
Lee JD, Heintz BH, Mosher HJ, et al. Risk of acute kidney injury and clostridioides difficile infection with piperacillin/tazobactam, cefepime, and meropenem with or without vancomycin [J]. Clin Infect Dis, 2021, 73(7): e1579-e1586.
|
| [38] |
Espi M, Teuma C, Novel-Catin E, et al. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study [J]. Eur J Cancer, 2021, 147: 29-39.
|
| [39] |
Gupta S, Short SAP, Sise ME, et al. Acute kidney injury in patients treated with immune checkpoint inhibitors [J]. J Immunother Cancer, 2021, 9(10): e003467.
|
| [40] |
Lunyera J, Clare RM, Chiswell K, et al. Racial differences in aki incidence following percutaneous coronary intervention [J]. J Am Soc Nephrol, 2021, 32(3): 654-662.
|
| [41] |
Mehran R, Owen R, Chiarito M, et al. A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry [J]. Lancet, 2021, 398(10315): 1974-1983.
|
| [42] |
Gaudry S, Hajage D, Martin-Lefevre L, et al. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial [J]. Lancet, 2021, 397(10281): 1293-1300.
|
| [43] |
Liu C, Peng Z, Dong Y, et al. Continuous renal replacement therapy liberation and outcomes of critically ill patients with acute kidney injury [J]. Mayo Clin Proc, 2021, 96(11): 2757-2767.
|
| [44] |
Naorungroj T, Neto AS, Murugan R, et al. Continuous renal replacement therapy: the interaction between fluid balance and net ultrafiltration [J]. Am J Respir Crit Care Med, 2021, 203(9): 1199-1201.
|
| [45] |
Roberts JA, Joynt GM, Lee A, et al. The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: data from the multinational sampling antibiotics in renal replacement therapy study [J]. Clin Infect Dis, 2021, 72(8): 1369-1378.
|
| [46] |
Pergola PE, Rosenbaum DP, Yang Y, et al. A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY) [J]. J Am Soc Nephrol, 2021, 32(6): 1465-1473.
|
| [47] |
Hill Gallant KM, Stremke ER, Trevino LL, et al. EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients [J]. Kidney Int, 2021, 99(5): 1225-1233.
|
| [48] |
Isaka Y, Hamano T, Fujii H, et al. Optimal phosphate control related to coronary artery calcification in dialysis patients [J]. J Am Soc Nephrol, 2021, 32(3): 723-735.
|
| [49] |
Ogata H, Fukagawa M, Hirakata H, et al. Effect of treating hyperphosphatemia with lanthanum carbonate vs calcium carbonate on cardiovascular events in patients with chronic kidney disease undergoing hemodialysis: the landmark randomized clinical trial [J]. JAMA, 2021, 325(19): 1946-1954.
|
| [50] |
Chan L, Chaudhary K, Saha A, et al. AKI in hospitalized patients with COVID-19 [J]. J Am Soc Nephrol, 2021, 32(1): 151-160.
|
| [51] |
Gupta S, Coca SG, Chan L, et al. AKI treated with renal replacement therapy in critically ill patients with COVID-19 [J]. J Am Soc Nephrol, 2021, 32(1): 161-176.
|
| [52] |
De Meester J, De Bacquer D, Naesens M, et al. Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: a regionwide registry study [J]. J Am Soc Nephrol, 2021, 32(2): 385-396.
|
| [53] |
Hsu CM, Weiner DE, Aweh G, et al. COVID-19 among US dialysis patients: risk factors and outcomes from a national dialysis provider [J]. Am J Kidney Dis, 2021, 77(5): 748-756.
|
| [54] |
May RM, Cassol C, Hannoudi A, et al. A multi-center retrospective cohort study defines the spectrum of kidney pathology in coronavirus 2019 disease (COVID-19) [J]. Kidney Int, 2021, 100(6): 1303-1315.
|
| [55] |
Diao B, Wang C, Wang R, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection [J]. Nat Commun, 2021, 12(1): 2506.
|
| [56] |
Govind D, Becker JU, Miecznikowski J, et al. Podosighter: a cloud-based tool for label-free podocyte detection in kidney whole-slide images [J]. J Am Soc Nephrol, 2021, 32(11): 2795-2813.
|
| [57] |
Ginley B, Jen KY, Han SS, et al. Automated computational detection of interstitial fibrosis, tubular atrophy, and glomerulosclerosis [J]. J Am Soc Nephrol, 2021, 32(4): 837-850.
|
| [58] |
Schena FP, Anelli VW, Trotta J, et al. Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy [J]. Kidney Int, 2021, 99(5): 1179-1188.
|
| [59] |
Zhang K, Liu X, Xu J, et al. Deep-learning models for the detection and incidence prediction of chronic kidney disease and type 2 diabetes from retinal fundus images [J]. Nat Biomed Eng, 2021, 5(6): 533-545.
|
| [60] |
Chan L, Nadkarni GN, Fleming F, et al. Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease [J]. Diabetologia, 2021, 64(7): 1504-1515.
|
| [61] |
Ayoub I, Wolf BJ, Geng L, et al. Prediction models of treatment response in lupus nephritis [J]. Kidney Int, 2022, 101(2): 379-389.
|